Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 49

Results For "Inc"

7922 News Found

Zota Health Care posts 83.86% revenue surge in FY26
Healthcare | May 25, 2026

Zota Health Care posts 83.86% revenue surge in FY26

Expands Davaindia network to 2,579 stores


EU regulator backs Allergan Aesthetics’ Boey in key step toward approval
Drug Approval | May 25, 2026

EU regulator backs Allergan Aesthetics’ Boey in key step toward approval

The decision marks a key step in the centralized EU review process


Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
R&D | May 25, 2026

Lilly brings heavy oncology firepower to ASCO with plenary data across cancers

The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy


Bristol Myers Squibb to unveil massive oncology data push at ASCO 2026
R&D | May 25, 2026

Bristol Myers Squibb to unveil massive oncology data push at ASCO 2026

The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”


AbbVie signals major oncology momentum at ASCO
R&D | May 25, 2026

AbbVie signals major oncology momentum at ASCO

With standout ADC and t-cell engager response data across hard-to-treat cancers


AstraZeneca to showcase cancer pipeline push at ASCO 2026
R&D | May 25, 2026

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies


Fortis Healthcare  FY26 revenue crosses Rs. 9,100 crore
Hospitals | May 23, 2026

Fortis Healthcare FY26 revenue crosses Rs. 9,100 crore

Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum


Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial
Clinical Trials | May 23, 2026

Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial

Clears major obesity endpoints at 80 weeks


Health ministry classifies Pregabalin under Schedule H1 to curb misuse
Policy | May 23, 2026

Health ministry classifies Pregabalin under Schedule H1 to curb misuse

New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain


ZIM Laboratories wins European regulatory milestone with anticoagulant approval in Italy
News | May 23, 2026

ZIM Laboratories wins European regulatory milestone with anticoagulant approval in Italy

The approval was granted by Agenzia Italiana del Farmaco